Description

MONTAIR LC TAB (1X15)

Indications

MONTAR LC TAB is primarily indicated for the management of allergic rhinitis and asthma. It is particularly effective in patients who suffer from both conditions, as it helps in alleviating symptoms related to nasal congestion, sneezing, runny nose, and wheezing. The formulation is suitable for both adults and children, making it a versatile option for those seeking relief from respiratory allergies and asthma-related symptoms.

Mechanism of Action

The active ingredients in MONTAR LC TAB include montelukast and levocetirizine. Montelukast is a leukotriene receptor antagonist that works by blocking the action of leukotrienes, which are inflammatory mediators involved in the pathophysiology of asthma and allergic rhinitis. By inhibiting these mediators, montelukast reduces bronchoconstriction, mucus secretion, and airway edema.

Levocetirizine, on the other hand, is an antihistamine that selectively antagonizes the H1 receptor, thereby preventing the action of histamine, which is responsible for allergy symptoms such as itching, swelling, and mucus production. Together, these two components provide a synergistic effect, leading to improved control of asthma symptoms and relief from allergic rhinitis.

Pharmacological Properties

MONTAR LC TAB exhibits a rapid onset of action, typically within one hour of administration. Montelukast has a half-life of approximately 2.7 to 5.5 hours, while levocetirizine has a half-life of about 7 to 10 hours, allowing for once-daily dosing. The drug is well absorbed after oral administration, with peak plasma concentrations reached within 1 to 3 hours. The bioavailability of montelukast is approximately 64%, and it is primarily metabolized in the liver via cytochrome P450 enzymes. Levocetirizine is excreted largely unchanged in the urine.

Contraindications

MONTAR LC TAB is contraindicated in patients with a known hypersensitivity to montelukast, levocetirizine, or any other component of the formulation. It should also be avoided in individuals with severe renal impairment or those undergoing hemodialysis, as the clearance of levocetirizine may be significantly reduced in these patients. Caution is advised in patients with a history of seizures or those taking medications that may lower the seizure threshold.

Side Effects

Common side effects associated with MONTAR LC TAB include drowsiness, fatigue, dry mouth, and gastrointestinal disturbances such as nausea and diarrhea. Less common but more serious side effects may include mood changes, depression, or allergic reactions such as rash, itching, or swelling. Patients should be advised to seek medical attention if they experience any severe or persistent side effects.

Dosage and Administration

The recommended dosage of MONTAR LC TAB for adults and children over the age of 12 is one tablet taken orally once daily in the evening. For children aged 6 to 11 years, the dosage is typically adjusted to half a tablet. It is essential to follow the prescribing physician’s instructions regarding dosage and duration of treatment. The tablets should be swallowed whole with water and can be taken with or without food.

Interactions

MONTAR LC TAB may interact with other medications, particularly those that are metabolized by the liver. Concomitant use of montelukast with other drugs that induce or inhibit cytochrome P450 enzymes may alter the plasma concentrations of montelukast. Additionally, levocetirizine may enhance the sedative effects of alcohol and other central nervous system depressants. Patients should inform their healthcare provider of all medications they are currently taking to avoid potential interactions.

Precautions

Patients should use MONTAR LC TAB with caution if they have a history of liver disease, as hepatic impairment may affect the metabolism of montelukast. It is also important to monitor patients for any signs of mood changes or suicidal thoughts, particularly in those with a history of depression or psychiatric disorders. Pregnant and breastfeeding women should consult their healthcare provider before using this medication to weigh the potential risks and benefits.

Clinical Studies

Clinical studies have demonstrated the efficacy of MONTAR LC TAB in reducing asthma exacerbations and improving overall asthma control. In a randomized controlled trial, patients receiving montelukast showed a significant reduction in nighttime awakenings due to asthma symptoms compared to placebo. Similarly, studies have indicated that levocetirizine effectively alleviates symptoms of allergic rhinitis, improving quality of life for patients. The combination of these two agents in MONTAR LC TAB has been shown to provide enhanced symptom relief and better control of both asthma and allergic rhinitis.

Conclusion

MONTAR LC TAB is a well-tolerated and effective treatment option for patients suffering from allergic rhinitis and asthma. Its unique combination of montelukast and levocetirizine provides comprehensive symptom relief and helps improve overall respiratory health. Patients should adhere to the prescribed dosage and consult their healthcare provider for any concerns regarding side effects or drug interactions. With appropriate use, MONTAR LC TAB can significantly enhance the quality of life for those affected by these conditions.